research
The Agitation Trial Reaches Hospice Care
A 120-person trial found a fixed THC-CBD formulation reduced agitation in hospice-eligible people with dementia compared with placebo.
Summary
A 120-person trial found a fixed THC-CBD formulation reduced agitation in hospice-eligible people with dementia compared with placebo.
Researchers presented results from the 120-participant LiBBY trial at the Alzheimer's Association International Conference. Hospice-eligible people with Alzheimer's disease or other dementias and significant agitation received a defined THC-CBD formulation or placebo; the research team reports significantly less agitation in the treatment group. Conference findings require full peer-reviewed detail to assess effect size, adverse events, and generalizability. The result concerns a controlled medical formulation in a narrowly defined population, not unsupervised cannabis use.
Why it matters
A 120-person trial found a fixed THC-CBD formulation reduced agitation in hospice-eligible people with dementia compared with placebo.
Limits and context
- The result concerns a controlled medical formulation in a narrowly defined population, not unsupervised cannabis use.
Key claims
A 120-person trial found a fixed THC-CBD formulation reduced agitation in hospice-eligible people with dementia compared with placebo.
Qualification: The result concerns a controlled medical formulation in a narrowly defined population, not unsupervised cannabis use.
Evidence: source-2026-07-14-013
Sources
- Georgetown University Medical Center via EurekAlert: LiBBY dementia agitation trialGeorgetown University Medical Center via EurekAlert · official announcement
Corrections
No corrections have been recorded for this story.